sph 3348
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 10, 2020 (NCT05088070)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06652997 | Phase 1 | Jul 15, 2022 | Government of China, Shanghai Pharmaceuticals Holding Co., Ltd, Sichuan University |
| NCT05088070 | Phase 1 | Jul 10, 2020 | Bengbu Medical College, Shanghai Pharmaceuticals Holding Co., Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Pharmaceuticals Holding Co., Ltd | For profit | 2 | 1 | 1 | 2020 |
| Bengbu Medical College | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Government of China | Government | 1 | 0 | 1 | 2022 |
| Sichuan University | Academic/Hospital | 1 | 1 | 1 | 2022 |
4 organizations
Page 1 / 1